FDA Panel Backs Reslizumab for Adults With Severe Asthma

The advisory committee ruled that evidence wasn't strong enough for recommending the drug for children aged 12 to 17 years, citing small numbers in studies; concerns include risk for anaphylaxis and muscle toxicity.